Gloria Galli

Dr. Gloria Galli

1Medical-Surgical Department of Clinical Sciences and Translational Medicine, Sant’Andrea Hospital, Sapienza University of Rome, Italy.
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2014 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GGGloria Galli
Gloria Galli
GEGianluca Esposito
Gianluca Esposito
ELE. Lahner
E. Lahner
EPE. Pilozzi
E. Pilozzi
VCV. D. Corleto
V. D. Corleto
BABruno Annibale
Bruno Annibale
Summary: Background: Adequate gluten‐free diet (GFD) is the only treatment for coeliac disease (CD). However, no agreement has been reached on either how and when to assess patient adherence toGFDor its effectiveness on villous atrophy.Aim: To assess, in a prospective study, patient adherence to and efficacy ofGFDon histological recovery after 1‐year ofGFD.Methods: Between 2009 and 2012, we enrolled 65 consecutive newly‐diagnosed adult patients (median age 38 years, 18–70) with biopsy‐proven atrophicCD. Patients were re‐evaluated after 1 year ofGFDwith duodenal histology, serological assays, symptoms and a dietary interview based on a validated questionnaire. Complete histological recovery was defined as the absence of villous atrophy and ≤30/100 intraepithelial lymphocytes.Results: Overall, 81.5% of patients had adequate adherence (ADA) toGFD, whereas 18.5% had an inadequate adherence (IADA); 66% ofADApatients and noIADApatients achieved complete histological recovery (P < 0.00001). AmongADApatients, antibody seroconversion and symptoms were not significantly different between patients who achieved complete histological recovery and those who achieved partial histological recovery withP = 0.309 andP = 0.197, respectively. Multivariate analysis showed that Marsh 3C was a risk factor for incomplete histological recovery inADApatients (OR8.74, 95%CI: 1.87–40.83).Conclusions: This study shows that complete histological recovery after 1‐year ofGFDin adult patients, who are assessed as adherent to theGFD, can be obtained in 66% of patients. Patients with severe histological damage at diagnosis are at risk for incomplete histological recovery 1 year later.

4 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
GGGloria Galli
Gloria Galli
GAGiulia Amici
Giulia Amici
LCLaura Conti
Laura Conti
ELEdith Lahner
Edith Lahner
BABruno Annibale
Bruno Annibale
MCMarilia Carabotti
Marilia Carabotti
Coeliac disease (CD) is an immune-mediated enteropathy triggered by gluten ingestion. At CD diagnosis, gender differences have been previously reported, but data regarding follow-up are scant. We investigated gender differences in CD adult patients both at the time of diagnosis and at follow-up after the start of the gluten-free diet (GFD). This is a longitudinal cohort study on adult CD patients diagnosed between 2008 and 2019. Clinical, biochemical, and histological data were assessed and compared between males and females. At diagnosis, female gender was significantly associated with signs of malabsorption (OR 3.39; 95% CI: 1.4–7.9), longer duration of symptoms and/or signs before the diagnosis (OR 3.39; 95% CI: 1.5–7.5), heartburn (OR 2.99; 95% CI: 1.1–8.0), dyspepsia (OR 2.70; 95% CI: 1.1–6.5), nausea/vomit (OR 3.53; 95% CI: 1.1–10.9), and constipation (OR 4.84; 95% CI: 1.2–19.6) and less frequently associated to higher body mass index (OR 0.88; 95% CI: 0.8–0.9) and osteopenia/osteoporosis (OR 0.30; 95% CI: 0.1–0.7) compared to male patients. After 12–30 months, females presented lower median BMI, performed less frequently histological control, and had more frequently anaemia and hypoferritinaemia compared to males. No significant differences concerning the presence of gastrointestinal symptoms, adherence to GFD, and Marsh score were found. Gender differences found at CD diagnosis mostly disappear at the follow-up, showing that these differences can be solved over time.

3 June 2014 in Gastric Cancer
Verified
Journal Article
Open access
PDF file
ELEdith Lahner
Edith Lahner
GEGianluca Esposito
Gianluca Esposito
EPEmanuela Pilozzi
Emanuela Pilozzi
GGGloria Galli
Gloria Galli
VCVito D. Corleto
Vito D. Corleto
BABruno Annibale
Bruno Annibale
Atrophic body gastritis (ABG) is associated with both type I gastric carcinoids (T1-GCs) and intestinal-type gastric cancer. The occurrence of gastric cancer in ABG patients with type I gastric carcinoids has not yet been described. To describe the occurrence at follow-up of gastric cancer in ABG patients with type I gastric carcinoid in a retrospective case series in a single tertiary referral center. Between 1994 and 2012, 17 new cases of T1-GCs were diagnosed among a cohort of ABG patients in a single tertiary referral center for ABG. The clinical charts of these 17 T1-GC patients were retrospectively evaluated for the occurrence of gastric cancer at follow-up (median 4.2 years, range 0.5–13). In 4 (23.5 %)/17 T1-GCs patients (3 females, age 40–78 years), gastric cancer occurred (median follow-up 5.9 years, range 5.1–13). Three cases were intestinal-type adenocarcinomas and one a signet-ring cell diffuse gastric cancer, localized in three cases in the antrum. In two patients, it was detected on random biopsies during follow-up gastroscopy; in the other two, gastroscopy was performed because of new symptoms. All patients with gastric cancer had associated autoimmune features (pernicious anemia, autoimmune thyroid disease and a spared antrum) compared to 77, 46 and 54 % of those without gastric cancer, although statistical significance was not reached. This case series shows that in patients with T1-GCs, gastric cancer may frequently occur at long-term follow-up. Thus, these patients should be monitored by a long-term surveillance program, including an accurate bioptic sampling of the antral mucosa.

12 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
GGGloria Galli
Gloria Galli
MCMarilia Carabotti
Marilia Carabotti
EPemanuela pilozzi
emanuela pilozzi
ELEdith Lahner
Edith Lahner
BABruno Annibale
Bruno Annibale
LCLaura Conti
Laura Conti
A gluten-free diet (GFD) leads to a rapid improvement in gastrointestinal (GI) symptoms, biochemical alterations and duodenal histological damage in the majority of celiac disease (CD) patients. This study aimed to assess the frequency and factors associated with the persistence of GI symptoms/malabsorption signs and their relationship with duodenal histological findings among CD patients on an adequate GFD (mean duration 16 months, range 12–28 months). This longitudinal cohort study included 102 adult CD patients (median age 38.5 years, range 18–76 years, F = 71.6%) diagnosed between 2012 and 2018. A total of 36.3% of the included patients had persistent GI symptoms and/or malabsorption signs (Group 1), while the remaining patients had complete GI well-being without malabsorption signs (Group 2) at the time of histological re-evaluation. The persistence of GI symptoms/signs was associated with a long duration of symptoms/signs before CD diagnosis (≥5 years) (OR 5.3; 95% CI 1.3–21.8) and the presence of constipation at the time of CD diagnosis (OR 7.5; 95% CI 1.3–42) while for other variables, including age at CD diagnosis, sex, duration of GFD, comorbidities, CD serology positivity and severity of duodenal damage at histological re-evaluation, no association was found. According to our results, the persistence of symptoms/signs is not associated with histological findings, and their relationship could be a gray area in CD management.

13 January 2014 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
ELEdith Lahner
Edith Lahner
EPEmanuela Pilozzi
Emanuela Pilozzi
GEGianluca Esposito
Gianluca Esposito
GGGloria Galli
Gloria Galli
BABruno Annibale
Bruno Annibale
Gastric carcinoids (GCs) represent 23% of all digestive neuroendocrine tumors (NETs). They can be distinguished into three types: type I (in the presence of atrophic body gastritis, ABG), type II (in the presence of Zollinger-Ellison/multiple endocrine neoplasia type I syndrome), type III (sporadic carcinoids, without any background pathology). To describe a case of undetermined type of GCs in an Italian referral center for NETs and its prevalence among GCs during a 6-year period. In a case series of 16 GCs seen at our unit between 2007 and 2012, 14 (83.3%) patients had type I carcinoid and 1 patient (6.2%) had type III carcinoid. One patient did not accomplish to the actual classification criteria. This patient had a well-differentiated carcinoid with low Ki67, but multiple gastric biopsies performed at 3-year follow-up gastroscopies excluded the presence of ABG. The patient had fundic cystic polyps, suggesting long-term use of proton pump inhibitors, possibly associated with GCs. This case shows that a GC may occur in the absence of ABG and with low Ki67 index, making classification according to actual criteria difficult. Further studies are needed to better understand the occurrence of this particular type of GCs.

12 June 2018 in United European Gastroenterology Journal
Verified
Journal Article
Open access
GGGloria Galli
Gloria Galli
ELEdith Lahner
Edith Lahner
LCLaura Conti
Laura Conti
GEGianluca Esposito
Gianluca Esposito
MSMaria Carlotta Sacchi
Maria Carlotta Sacchi
BABruno Annibale
Bruno Annibale
Up to 75% of patients with untreated coeliac disease (CD) present with osteopenia or osteoporosis. Guidelines do not express with certainty whether each patient with newly diagnosed CD should undergo a dual-energy x-ray absorptiometry (DEXA) scan. The aim of this article is to evaluate the prevalence of bone mineral density (BMD) alterations at diagnosis and risk factors associated with osteoporosis. A total of 214 adult patients (median age 38 years; female = 71.5%) newly diagnosed with CD underwent DEXA. The patients were divided into three groups: patients with normal BMD, those with osteopenia and those with osteoporosis. Clinical, histological and serological features were assessed and compared among the three groups. Logistic regression including relevant independent variables was performed. DEXA indicated that 39.7%, 42.5% and 17.8% of the CD patients had normal BMD, osteopenia and osteoporosis, respectively. Logistic regression indicated that features significantly associated with osteoporosis were male gender (OR 4.7; 95%CI 1.1 to 20.8), age ≥45 years (OR 6.5; 95% CI 1.3 to 32.2), underweight (OR 7.4; 95% CI 1.3 to 42.5) and greater histological damage (Marsh 3C; OR 5.8; 95% CI 1.4 to 24.1). BMD alterations were found in 60.3% of newly diagnosed adult coeliac patients. Osteoporosis was significantly associated with age ≥45 years, male gender, underweight and Marsh 3C, suggesting that at CD diagnosis, a DEXA scan might be beneficial, particularly in these subgroups of patients.